Ramipril Capsule
Product Images NDC 51655-347

5 FDA label images from Northwind Health Company, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Ramipril (NDC 51655-347). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula For Ramipril (C73b9a08 9128 464e 9a01 040977af1368 01)

Structural Formula For Ramipril (C73b9a08 9128 464e 9a01 040977af1368 01)
Chemical structure of Ramipril, showing its molecular arrangement with rings, bonds, and functional groups. The diagram depicts atoms and bonds typical of the Ramipril molecule used in oral capsule formulation.*
FDA Label Image

Graph1 (C73b9a08 9128 464e 9a01 040977af1368 02)

Graph1 (C73b9a08 9128 464e 9a01 040977af1368 02)
A line graph comparing the proportion of patients over days of follow-up between Ramipril and placebo groups. The x-axis represents days of follow-up up to approximately 1600, and the y-axis shows the proportion of patients up to 0.20. Two lines show patient proportions over time: a solid line for Ramipril and a dashed line for placebo, with a p-value of 0.0001 indicating statistical significance.*
FDA Label Image

Graph2 (C73b9a08 9128 464e 9a01 040977af1368 03)

Graph2 (C73b9a08 9128 464e 9a01 040977af1368 03)
A forest plot chart depicting the relative risk in the Ramipril group versus placebo for various patient subgroups, including cardiovascular disease presence, diabetes, age groups, sex, hypertension, coronary artery disease history, myocardial infarction history, cerebrovascular disease, peripheral vascular disease, and microalbuminuria status. The chart shows number of patients and incidence rates in the placebo group, with confidence interval markers around a central relative risk line.*
FDA Label Image

Image (32265d51 201f 404a 8762 14f10a8df969 350 1)

Image (32265d51 201f 404a 8762 14f10a8df969 350 1)
Ramipril 2.5 mg oral capsules shown in a blister pack. The pack contains multiple capsules arranged in a grid with a foil backing. No additional text or branding visible on the blister pack itself.*
FDA Label Image

Label (51655 347 52 Rev B 03 22 Nhc)

Label (51655 347 52   Rev B 03 22 Nhc)
Ramipril Capsules, USP 2.5 mg oral capsules in a package of 30 capsules, labeled for prescription use only. The label includes storage instructions and dosage information. The product is labeled by Northwind Health Company, LLC with NDC 51655-347-52.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.